What is Relmada Therapeutics, Inc.'s net sales percentage?

Relmada Therapeutics, Inc. (RLMD) reported net sales percentage of 3% in Q1 2026.

What does net sales percentage mean?

The ratio of net sales to total revenue or a specific benchmark, used to evaluate the contribution of core product sales to the company's overall financial performance. For early-stage companies, this highlights the transition from research-focused activities to commercial revenue generation.

Relmada Therapeutics, Inc. RLMD Net Sales Percentage

Net Sales Percentage at other companies

Evommune EVMN

96%+3.0pp

Lands' End, Inc.LE

23.1%+0.3pp

Evommune EVMN

96%+3.0pp

RBC BearingsRBC

13%-5.0pp

Lowe's CompaniesLOW

100%0.0pp

Haverty Furniture CompaniesHVT

100%0.0pp

Other financials

Income statement

See full

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Balance sheet

See full

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Cash flow

See full

Operating cash flow-$15.1M+16.6%

Valuation

See full

Market cap$677.17M+2,907%

Returns & leverage

See full

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept rlmd:NetSalesPercentage.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s net sales percentage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s net sales percentage?: Relmada Therapeutics, Inc. (RLMD) reported net sales percentage of 3% in Q1 2026.
What does net sales percentage mean?: The ratio of net sales to total revenue or a specific benchmark, used to evaluate the contribution of core product sales to the company's overall financial performance. For early-stage companies, this highlights the transition from research-focused activities to commercial revenue generation.